Past Performance: Past Performance is not an indicator of future results.
Founded in Australia in 1916, Commonwealth Serum Laboratories (CSL) is a prominent medical and biotech company. CSL Ltd has three primary segments: CSL Behring, CSL Plasma and Seqirus. CSL Behring is an international biotechnology leader, CSL Plasma is the world's largest collector of human blood plasma and Seqirus specialises in the development of influenza vaccines.[1] Headquartered in Melbourne, AUS, CSL Ltd features divisions across the Americas, Asia, Asia Pacific and Europe.
Shares of CSL Ltd (CSL) are primarily listed for trade on the Australian Securities Exchange (ASX). In addition, shares of CSL Ltd are available over-the-counter in the U.S. under the symbols CSLLY and CUSIP.[2] CSL's standing has made it a constituent of the ASX 200 stock index.[3]
| Retrieved 25 Aug 2021 https://www.csl.com/our-company/our-story | |
| Retrieved 25 Aug 2021 https://investors.csl.com/site/investors/shareholder-information/shareholder-services | |
| Retrieved 25 Aug 2021 https://www.asx200list.com/ |
| Retrieved 25 Aug 2021 https://www.csl.com/our-company/our-story | |
| Retrieved 25 Aug 2021 https://investors.csl.com/site/investors/shareholder-information/shareholder-services | |
| Retrieved 25 Aug 2021 https://www.asx200list.com/ |
When executing customers' trades, FXCM can be compensated in several ways, which include, but are not limited to: spreads, charging commissions at the open and close of a trade, and adding a mark-up to rollover, etc. Commission-based pricing is applicable to Active Trader account types.
Third Party Links: Links to third-party sites are provided for your convenience and for informational purposes only. FXCM bears no liability for the accuracy, content, or any other matter related to the external site or for that of subsequent links, and accepts no liability whatsoever for any loss or damage arising from the use of this or any other content. Such sites are not within our control and may not follow the same privacy, security, or accessibility standards as ours. Please read the linked websites' terms and conditions.
Any opinions, news, research, analyses, prices, other information, or links to third-party sites contained on this website are provided on an "as-is" basis, as general market commentary and do not constitute investment advice. The market commentary has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is therefore not subject to any prohibition on dealing ahead of dissemination. Although this commentary is not produced by an independent source, FXCM takes all sufficient steps to eliminate or prevent any conflicts of interests arising out of the production and dissemination of this communication. The employees of FXCM commit to acting in the clients' best interests and represent their views without misleading, deceiving, or otherwise impairing the clients' ability to make informed investment decisions. For more information about the FXCM's internal organizational and administrative arrangements for the prevention of conflicts, please refer to the Firms' Managing Conflicts Policy. Please ensure that you read and understand our Full Disclaimer and Liability provision concerning the foregoing Information, which can be accessed here.